G2-TR intraocular implant containing travoprost

COMBINATION_PRODUCT2 trials

Sponsors

Glaukos Corporation

Conditions

Glaucoma, Open-AngleOcular Hypertension

Phase 3

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

CompletedNCT03519386

Glaukos CorporationGlaucoma, Open-Angle, Ocular Hypertension

Start: 2018-07-26End: 2024-04-02Updated: 2024-11-29

Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

CompletedNCT03868124

Glaukos CorporationGlaucoma, Open-Angle, Ocular Hypertension

Start: 2018-09-17End: 2024-06-19Updated: 2024-11-29

Related Papers

Administration of the Travoprost Intracameral Implant in an Office-Based Surgery Setting.

2025-10-04

Long-Term Safety and Efficacy Evaluation of Travoprost Intracameral Implant Based on Pooled Analyses from Two Phase III Trials

Drugs2024-09-0615 citations

Travoprost Intracameral Implant Demonstrates Superior IOP Lowering Versus Topical Prostaglandin Analog Monotherapy in Patients with Open-Angle Glaucoma or Ocular Hypertension.

2024-07-101 citations

Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial

Ophthalmology and Therapy2024-02-1223 citations

Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension.

2023-12-0718 citations

Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.

2022-12-0130 citations